Key result
An SDNN < 110 ms was an independent risk factor for poorer overall survival in patients with hepatocellular carcinoma (HR 3.646; 95% CI 2.143 to 6.205).
Why the study?
Heart rate variability indices are associated with prognosis in various cancers, but their ability to predict survival in patients with hepatocellular carcinoma after diagnosis needed evaluation.
Does reduced heart rate variability (SDNN < 110 ms) predict overall survival in patients with hepatocellular carcinoma?
Cohort (n=231)
Does reduced heart rate variability (SDNN < 110 ms) predict overall survival in patients with hepatocellular carcinoma?
Hazard Ratio: 3.646 (95% CI 2.143–6.205)
Reduced heart rate variability (SDNN < 110 ms) is a strong independent predictor of mortality in patients with hepatocellular carcinoma.
BACKGROUND: Heart rate variability (HRV) indices have been shown to be associated with prognosis in various types of cancer. This study aims to assess the ability of these indices to predict survival in hepatocellular carcinoma (HCC) patients after diagnosis. METHODS: We retrospectively collected data from 231 patients diagnosed with HCC between January 2014 and March 2018. The baseline clinical-pathological variables and HRV indices (extracted from Holter electrocardiogram recordings) were analyzed. RESULTS: Univariate and multivariate analyses were performed to identify the predictive value of the above factors for overall survival (OS). The univariate analysis revealed that an age > 60 years, hepatitis C, portal vein involvement (thrombosis), a tumor size > 5 cm, alpha-fetoprotein (AFP) > 400 ng/mL, serum albumin, and C-reactive protein (CRP) were risk factors for poor OS. Multivariable Cox regression analyses identified that a tumor size > 5 cm and AFP > 400 ng/mL predict poorer outcomes in HCC patients. It should be mentioned that, in both the univariate analysis and in the multivariate analysis, between HRV indices, SDNN (standard deviation of all normal-to-normal (NN) intervals) < 110 ms was an independent risk factor for OS with an HR of 3.646 (95% CI 2.143 to 6.205). CONCLUSION: This study demonstrates that HRV indices identify HCC patients at high risk of death and suggests that such monitoring might guide the need for early therapy in these types of patients, as well as the fact that HRV can be a potential noninvasive biomarker for HCC prognosis.
No takes yet. Share an insight, caveat, or question.
Ciurea et al. (2021) conducted a cohort in Hepatocellular carcinoma (n=231). SDNN < 110 ms was evaluated on Overall survival (HR 3.646, 95% CI 2.143 to 6.205). An SDNN < 110 ms was an independent risk factor for poorer overall survival in patients with hepatocellular carcinoma (HR 3.646; 95% CI 2.143 to 6.205).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: